BioDelivery Sciences misses top endpoint in Ph3 for pain drug; InSite reveals upbeat mid-stage data on anti-pain treatment;

> BioDelivery Sciences International ($BDSI), which uses drug-delivery technologies in its development of new treatments, said it did not meet the primary endpoint of its late-stage study of BEMA Buprenorphine for moderate to severe chronic pain. Release

> The Medicines Company ($MDCO) said that it has commercially released a 12-hour version of the blood-pressure drug clevidipine for injection. The FDA approved the formulation in June. Item

> InSite Vision ($INSV) reported upbeat data from a mid-stage study of its BromSite treatment, which uses its DuraSite delivery technology, for the treatment of pain and inflammation from ocular surgery. Announcement

> India's Sparsha Pharma International, a maker of fentanyl patches, said it has begun to commercialize to next-gen transdermal patches for use in treating pain. Item